Page 10 - Fixed Dose Combination News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Late-hour selling drags Nifty below 15,750 mark, Sensex slides 67 pts

Late-hour selling drags Nifty below 15,750 mark, Sensex slides 67 pts
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

India generalUttar pradeshTamil naduNew delhiVindhya telelinksSabitgarh distt bulandshaharMilak narayanpurAurobindo pharmaTenofovir disoproxil fumarateTorrent pharmaceuticalsSun pharmaceutical industriesCorporation of indiaTriveni engineering industriesMinistry of healthEmcure pharmaceuticalsHealth ministry lav agarwal

Nifty ends below 15,750; pharma shares decline

Nifty ends below 15,750; pharma shares decline
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

Tamil naduNew delhiUttar pradeshAbu dhabiVindhya telelinksSabitgarh distt bulandshaharMilak narayanpurAurobindo pharmaTenofovir disoproxil fumarateTorrent pharmaceuticalsSun pharmaceutical industriesCorporation of indiaMinistry of healthTriveni engineering industriesEmcure pharmaceuticalsOdisha power generation corporation

Lupin receives tentative U S FDA approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR

Lupin receives tentative U S FDA approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

United statesNaresh guptaTenofovir disoproxil fumarateLupin limitedDrug administrationUs agency for international developmentWorld health organisationTime zoneUnited states foodEmergency planNew drug applicationFixed dose combinationInternational developmentஒன்றுபட்டது மாநிலங்களில்னரேஷ் குப்தாலூபின் வரையறுக்கப்பட்டவை

Glenmark launches fixed-dose combination drug for diabetes

Glenmark is the first company in the world to launch Remogliflozin (100 mg) + Vildagliptin (50 mg) Fixed Dose Combination (FDC) at an affordable price for adults with type 2 diabetes in India.Glenmark Pharmaceuticals has launched a fixed dose combination of its novel, patent protected and globally researched sodium glucose co-transporter inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) - Vildagliptin, in India. The fixed drug combination is indicated for the management of Type 2 diabetes. The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo V and Remozen V.

Remogliflozin etabonateIndia glenmark pharmaceuticalsGlenmark pharmaceuticalsFixed dose combinationDipeptidyl peptidaseCapital marketஇந்தியா க்ளேண்மர்க் மருந்துகள்க்ளேண்மர்க் மருந்துகள்சரி செய்யப்பட்டது டோஸ் சேர்க்கைமூலதனம் சந்தை

European Commission approves Roche s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer – IT Business Net

European Commission approves Roche s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesNathalie meetzHalozyme enhanzeLevi garrawayDaniel grotzkyPatrick barthKarsten kleineDrug delivery technologyEuropean commissionDrug administrationHead of global product developmentRoche groupPharmaceuticals industrySafety of subcutaneous administration theRoche group media relations